~12 spots leftby Apr 2026

NEAAR Medical Food for Rectal Cancer

(NEAAR-LARC Trial)

Recruiting in Palo Alto (17 mi)
RR
Overseen byRichard R Tuli, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: University of South Florida
Must not be taking: Protein supplements
Disqualifiers: Insulin-dependent diabetes, Cachexia, others
No Placebo Group

Trial Summary

What is the purpose of this trial?

This clinical study aims to assess feasibility, safety, tolerability, and compliance of a Nonessential Amino Acid Restriction (NEAAR) medical food in adult patients with locally advanced rectal cancer during standard of care short course radiotherapy followed by standard of care chemotherapy.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot take any protein or amino acid supplements.

What data supports the effectiveness of the NEAAR Medical Food treatment for rectal cancer?

Research shows that certain nutritional approaches, like those involving amino acids and other nutrients, can help improve recovery and reduce complications in cancer patients. For example, a study found that glutamine, an amino acid, reduced postoperative complications and improved recovery in rectal cancer patients. This suggests that similar nutritional strategies, like NEAAR Medical Food, might also be beneficial.12345

Is NEAAR Medical Food safe for humans?

Medical foods, like NEAAR Medical Food, are designed to be safe and are made with ingredients that are generally recognized as safe (GRAS). They are used under a doctor's guidance for managing specific health conditions.678910

How does the NEAAR Medical Food treatment for rectal cancer differ from other treatments?

The NEAAR Medical Food treatment for rectal cancer is unique because it focuses on nutritional intervention, potentially using specific food components to support health during cancer treatment. Unlike traditional treatments like chemotherapy or radiation, this approach may involve dietary changes or supplements to improve nutritional status and overall well-being, although its direct impact on cancer progression is not well-established.1112131415

Research Team

RR

Richard R Tuli, MD

Principal Investigator

University of South Florida

Eligibility Criteria

This trial is for adults with locally advanced rectal cancer. Participants should be able to follow a special diet (NEAAR Medical Food) during standard radiotherapy and chemotherapy treatments.

Inclusion Criteria

My cancer has not spread to distant parts of my body.
My diagnosis is rectal adenocarcinoma.
My cancer is at stage II or III according to MRI results.
See 4 more

Exclusion Criteria

Receiving other anticancer or experimental therapy
I use insulin for my diabetes.
Patients unable to undergo MRI
See 6 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Radiation

Participants receive standard of care short course radiotherapy

1-2 weeks

Chemotherapy

Participants receive standard of care chemotherapy in combination with NEAAR medical food

8-12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • NEAAR Medical Food (Other)
Trial OverviewThe study tests the NEAAR Medical Food's effects on patients undergoing typical treatment for rectal cancer, including its feasibility, safety, how well people can stick to it, and if it causes any discomfort.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Nonessential Amino Acid Restriction (NEAAR) Medical FoodExperimental Treatment1 Intervention
This is a single arm study in which all subjects will receive NEAAR medical food.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of South Florida

Lead Sponsor

Trials
433
Recruited
198,000+
Dr. Barbara White profile image

Dr. Barbara White

University of South Florida

Chief Medical Officer since 2021

MD, University of Pennsylvania School of Medicine

Dr. Sylvia W. Thomas profile image

Dr. Sylvia W. Thomas

University of South Florida

Chief Executive Officer since 2023

Ph.D. in Electrical Engineering, University of South Florida

Findings from Research

In a study of 154 patients recovering from upper gastrointestinal surgery, early enteral feeding with an immunonutritional diet (supplemented with arginine, dietary nucleotides, and omega-3 fatty acids) significantly reduced late postoperative complications compared to a standard control diet, with fewer patients experiencing issues after the fifth postoperative day (5 vs. 13).
The immunonutrition group also demonstrated a substantial cost reduction in treating complications, amounting to approximately 38,867 German marks less than the control group, highlighting both clinical and economic benefits of this dietary intervention.
Early postoperative enteral immunonutrition: clinical outcome and cost-comparison analysis in surgical patients.Senkal, M., Mumme, A., Eickhoff, U., et al.[2019]
In a longitudinal study of colorectal cancer patients, symbiotic supplementation led to a significant reduction in C-reactive protein (CRP) levels from 11 mg/dL to below 6 mg/dL, indicating decreased systemic inflammation.
While albumin and carcino-embryonic antigen (CEA) levels remained stable, the reduction in CRP suggests that symbiotic supplementation may help improve the nutritional status and inflammatory response in these patients.
Nutritional status and systemic inflammatory activity of colorectal patients on symbiotic supplementation.de Oliveira, AL., Aarestrup, FM.[2019]
In a pilot study involving 22 colorectal cancer patients, the amino-acid-rich elemental diet Elental(®) significantly reduced the severity of chemotherapy-induced oral mucositis, with 18 out of 22 patients showing improvement during the first treatment course (p = 0.0002) and 20 out of 22 during the second course (p < 0.0001).
Factors such as the intake of Elental(®), prior use of the diet, and dose reductions of chemotherapy drugs were identified as significant contributors to its effectiveness in preventing oral mucositis.
Preventive effects of amino-acid-rich elemental diet Elental® on chemotherapy-induced oral mucositis in patients with colorectal cancer: a prospective pilot study.Ogata, Y., Ishibashi, N., Yamaguchi, K., et al.[2022]

References

Early postoperative enteral immunonutrition: clinical outcome and cost-comparison analysis in surgical patients. [2019]
Nutritional status and systemic inflammatory activity of colorectal patients on symbiotic supplementation. [2019]
Preventive effects of amino-acid-rich elemental diet Elental® on chemotherapy-induced oral mucositis in patients with colorectal cancer: a prospective pilot study. [2022]
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. [2022]
Effect of Glutamine on Short-term Surgical Outcomes in Rectal Cancer Patients Receiving Neoadjuvant Therapy: A Propensity Score Matching Study. [2023]
Medical foods: products for the management of chronic diseases. [2019]
The Emerging Therapeutic Role of Medical Foods for Gastrointestinal Disorders. [2020]
Things We Do For No Reason: Neutropenic Diet. [2019]
Proposals for Upper Limits of Safe Intake for Methionine, Histidine, and Lysine in Healthy Humans. [2023]
Are there dietary requirements for dispensable amino acids and if so, how do we assess requirements? [2020]
[Nutrition and cancer: causative, protective and therapeutic aspects]. [2018]
Dietary supplementation with rice bran or navy bean alters gut bacterial metabolism in colorectal cancer survivors. [2022]
13.United Statespubmed.ncbi.nlm.nih.gov
Food items and food groups as risk factors in a case-control study of diet and colo-rectal cancer. [2019]
[Nutrition and colorectal cancer]. [2017]
15.United Statespubmed.ncbi.nlm.nih.gov
Nutritional, immunological and antioxidant defense status of outpatients diagnosed with colorectal cancer - a case-control study of the little-studied population. [2021]